Results 151 to 160 of about 12,575 (207)
Effectiveness of simplifying antiretroviral therapy to maintain viral suppression and improve bone and renal health: comparing simplified and non-simplified therapy. [PDF]
Braz J Infect DisRodrigues JO +3 more
europepmc +1 more source
The fate of ritonavir in the presence of darunavir [PDF]
International Journal of Pharmaceutics, 2014 This study was the first investigation into the potential of a fixed dose combination of ritonavir and darunavir in the form of dispersible powders prepared by spray drying.
G Van Den Mooter
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs of Today, 2007
Darunavir is a nonpeptidic protease inhibitor recently approved for the treatment of antiretroviral therapy-experienced patients. It has potent in vitro activity against viral isolates that are resistant to currently licensed protease inhibitors. In randomized clinical trials with optimized background regimens, it has shown virologic and immunologic ...
Wissam I, El-Atrouni, Zelalem, Temesgen
openaire +4 more sources
Darunavir is a nonpeptidic protease inhibitor recently approved for the treatment of antiretroviral therapy-experienced patients. It has potent in vitro activity against viral isolates that are resistant to currently licensed protease inhibitors. In randomized clinical trials with optimized background regimens, it has shown virologic and immunologic ...
Wissam I, El-Atrouni, Zelalem, Temesgen
openaire +4 more sources
Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients [PDF]
Pharmacological Research, 2012 The potential drug-to-drug interaction between darunavir and raltegravir in the setting of HIV infection is a highly debated issue still unresolved.
Dario Cattaneo +2 more
exaly +2 more sources
Pharmacoeconomics of darunavir
Expert Review of Pharmacoeconomics & Outcomes Research, 2011Darunavir boosted with ritonavir (DRV/r) in combination with other antiretrovirals (ARVs) was initially approved in 2006 for the treatment of HIV infection in ARV treatment-experienced adults and has subsequently been approved for use in treatment-naive adults in 2008.
Dwight S, Fullerton +3 more
openaire +2 more sources
Darunavir: A comprehensive profile
2021Darunavir: (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl] (isobutyl)amino}-3-hydroxy-1-phenyl-2-butanyl]carbamate is a synthetic non-peptide protease inhibitor. On June 2006, it was first approved by the Food and Drug administration (FDA) for treatment of resistant type-1 of the human immunodeficiency virus (HIV).
Ibrahim A, Darwish +5 more
openaire +2 more sources